Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer
Anshu Giri1, Simrit S Walia, Ajeet Gajra
1Upstate University Hospital, Department of Medicine, 750 East Adams St, Syracuse, NY 13210, USA.
Introduction:
Non-Small Cell Lung Cancer (NSCLC) is an aggressive malignancy with poor overall survival that accounts for up to 85% of lung cancer diagnoses. The use of immunotherapy in the form of checkpoint inhibition, to enhance the immune system's ability to attack malignant cells, has been a promising addition to treatment options in advanced NSCLC.
Results:
Such therapeutic agents aimed at the Programmed Death 1 (PD-1) receptor or Programmed Death Ligand 1 (PD-L1) have revealed promising results against many types of cancer including NSCLC. Examples of these agents include nivolumab, pembrolizumab, BMS-936559, atezolizumab, and MEDI4736, of which the first two are approved by US FDA in the second line treatment of advanced NSCLC.
Discussion:
Impressive improvements in objective responses from PD-1 blockade were found in both first line therapy as well as treatment after progression on platinum based therapy. In addition, the safety profile is favorable with significantly lower grade 3-4 adverse events compared to standard of care. The optimal selection criteria and factors that show an increased response to therapy are still being determined.
Insights
Immunotherapy using Programmed Death 1 (PD-1) blockade shows promise for advanced Non-Small Cell Lung Cancer (NSCLC). This approach enhances immune response and offers a favorable safety profile compared to traditional treatments.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Non-Small Cell Lung Cancer (NSCLC) is a leading cause of cancer death, characterized by poor survival rates.
- Immunotherapy, specifically checkpoint inhibition, offers a novel strategy to augment the host immune system against cancer.
- Advanced NSCLC treatment remains a significant clinical challenge, necessitating innovative therapeutic approaches.
Purpose of the Study:
- To evaluate the efficacy and safety of Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) pathway inhibitors in advanced NSCLC.
- To review the clinical outcomes of PD-1 blockade in various treatment settings for NSCLC.
- To assess the safety profile of PD-1 targeted immunotherapies.
Main Methods:
- Review of clinical studies and FDA-approved agents targeting the PD-1/PD-L1 pathway.
- Analysis of objective response rates and adverse events associated with PD-1 blockade.
- Examination of treatment outcomes in first-line and second-line settings for advanced NSCLC.
Main Results:
- PD-1 blockade demonstrates significant objective responses in advanced NSCLC, both as first-line therapy and after platinum-based treatment.
- Approved agents like nivolumab and pembrolizumab are effective in second-line treatment.
- The safety profile is favorable, with a notable reduction in severe (grade 3-4) adverse events compared to standard care.
Conclusions:
- PD-1 blockade represents a promising immunotherapy for advanced NSCLC, improving treatment outcomes.
- Further research is needed to identify optimal patient selection criteria and predictive biomarkers for enhanced therapeutic response.
- Immunotherapy offers a well-tolerated and effective treatment option for patients with advanced NSCLC.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...